story of the week
Fluorouracil, Epirubicin, and Cyclophosphamide (FEC-75) Followed by Paclitaxel Plus Trastuzumab Versus Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab as Neoadjuvant Treatment for Patients With HER2-Positive Breast Cancer (Z1041): A Randomised, Controlled, Phase 3 Trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology